Bank of America Corp DE Trims Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Bank of America Corp DE decreased its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 43.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 62,260 shares of the company’s stock after selling 48,772 shares during the period. Bank of America Corp DE owned 0.10% of Kymera Therapeutics worth $2,505,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the business. BNP Paribas Financial Markets purchased a new position in shares of Kymera Therapeutics in the fourth quarter worth about $396,000. Ameriprise Financial Inc. purchased a new position in Kymera Therapeutics during the fourth quarter valued at approximately $344,000. Boxer Capital Management LLC purchased a new position in Kymera Therapeutics during the fourth quarter valued at approximately $17,098,000. Soros Fund Management LLC purchased a new position in Kymera Therapeutics during the fourth quarter valued at approximately $4,843,000. Finally, Schonfeld Strategic Advisors LLC grew its stake in Kymera Therapeutics by 20.3% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 215,480 shares of the company’s stock valued at $8,669,000 after acquiring an additional 36,294 shares in the last quarter.

Kymera Therapeutics Stock Performance

Shares of KYMR opened at $29.46 on Monday. The firm has a market cap of $1.92 billion, a price-to-earnings ratio of -12.59 and a beta of 2.18. Kymera Therapeutics, Inc. has a fifty-two week low of $19.45 and a fifty-two week high of $53.27. The firm has a 50 day moving average price of $28.58 and a 200-day moving average price of $35.58.

Kymera Therapeutics (NASDAQ:KYMR) last issued its earnings results on Friday, May 9th. The company reported ($0.82) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.10. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The company had revenue of $22.10 million for the quarter, compared to the consensus estimate of $11.38 million. During the same period in the previous year, the firm earned ($0.69) earnings per share. The firm’s revenue for the quarter was up 114.6% on a year-over-year basis. As a group, equities research analysts predict that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Guggenheim reaffirmed a “buy” rating and set a $52.00 price objective on shares of Kymera Therapeutics in a research note on Monday, May 12th. Stifel Nicolaus assumed coverage on shares of Kymera Therapeutics in a research note on Tuesday, May 20th. They set a “buy” rating and a $55.00 price objective for the company. UBS Group reduced their price objective on shares of Kymera Therapeutics from $72.00 to $70.00 and set a “buy” rating for the company in a research note on Tuesday, May 13th. Wall Street Zen raised shares of Kymera Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, May 22nd. Finally, Bank of America reduced their price objective on shares of Kymera Therapeutics from $47.00 to $44.00 and set a “neutral” rating for the company in a research note on Monday, May 12th. Five equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $55.25.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.